ReviewDrug discovery today2013
Towards the use of hydrogels in the treatment of limbal stem cell deficiency.
Review in Drug discovery today, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Concise Review: Considering Optimal Temperature for Short-Term Storage of Epithelial Cells.Frontiers in medicine · 2021Pooled it
- Bio-printing method as a novel approach to obtain a fibrin scaffold settled by limbal epithelial cells for corneal regeneration.Scientific reports · 2024Article
- Preparation and In Vitro Characterization of Gelatin Methacrylate for Corneal Tissue Engineering.Tissue engineering and regenerative medicine · 2022Article
- Supramolecular host-guest hyaluronic acid hydrogels enhance corneal wound healing through dynamic spatiotemporal effects.The ocular surface · 2022Article
- Bioprinting of dual ECM scaffolds encapsulating limbal stem/progenitor cells in active and quiescent statuses.Biofabrication · 2021Article
- Biomechanical Modulation Therapy-A Stem Cell Therapy Without Stem Cells for the Treatment of Severe Ocular Burns.Translational vision science & technology · 2020Article
- Bioengineering Approaches for Corneal Regenerative Medicine.Tissue engineering and regenerative medicine · 2020Review
- Cellular therapy of corneal epithelial defect by adipose mesenchymal stem cell-derived epithelial progenitors.Stem cell research & therapy · 2020Article
- Smart Carriers and Nanohealers: A Nanomedical Insight on Natural Polymers.Materials (Basel, Switzerland) · 2017Review
- Tissue-engineered cornea constructed with compressed collagen and laser-perforated electrospun mat.Scientific reports · 2017Article
- [The emerging technology of tissue engineering : Focus on stem cell niche].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Review
- Induced pluripotent stem cells, formJournal of thoracic disease · 2017Article
- A Bioengineering Approach to Myopia Control Tested in a Guinea Pig Model.Investigative ophthalmology & visual science · 2017Article
- Bioprinting three-dimensional cell-laden tissue constructs with controllable degradation.Scientific reports · 2016Article
- Synthetic vs natural scaffolds for human limbal stem cells.Croatian medical journal · 2015Article
- Hydrogels for ocular drug delivery and tissue engineering.BioImpacts : BI · 2015Article
- Y-27632, a ROCK Inhibitor, Promoted Limbal Epithelial Cell Proliferation and Corneal Wound Healing.PloS one · 2015Article
- Oxidized alginate hydrogels as niche environments for corneal epithelial cells.Journal of biomedical materials research. Part A · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Corneal blindness caused by limbal stem cell deficiency (LSCD) is a prevailing disorder worldwide. Clinical outcomes for LSCD therapy using amniotic membrane (AM) are unpredictable. Hydrogels can eliminate limitations of standard therapy for LSCD, because they present all the advantages of AM (i.e. biocompatibility, inertness and a biodegradable structure) but unlike AM, they are structurally uniform and can be easily manipulated to alter mechanical and physical properties. Hydrogels can be delivered with minimum trauma to the ocular surface and do not require extensive serological screening before clinical application. The hydrogel structure is also amenable to modifications which direct stem cell fate. In this focussed review we highlight hydrogels as biomaterial substrates which may replace and/or complement AM in the treatment of LSCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.